Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

PHASE3CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Severe Hemophilia A
Interventions
DRUG

Factor VIII (rFVIIIFc)

DRUG

Advate®

Trial Locations (64)

1023

Research Site, Auckland

1090

Research Site, Vienna

1200

Research Site, Brussels

4442

Research Site, Palmerston North

8001

Research Site, Christchurch

19104

Research Site, Philadelphia

19107

Research Site, Philadelphia

41345

Research Site, Gothenburg

52621

Research Site, Ramat Gan

69437

Research Site, Lyon

Unknown

Research Site, Little Rock

Research Site, Los Angeles

Research Site, Orange

Research Site, Sacramento

Research Site, San Diego

Research Site, Washington D.C.

Research Site, Indianapolis

Research Site, Iowa City

Research Site, Louisville

Research Site, New Orleans

Research Site, Boston

Research Site, East Lansing

Research Site, Las Vegas

Research Site, New York

Research Site, Chapel Hill

Research Site, Pittsburgh

Research Site, Houston

Research Site, Salt Lake City

Research Site, Seattle

Research Site, Camperdown

Research Site, Adelaide

Research Site, Perth

Research Site, Campinas

Research Site, Toronto

Research Site, Bonn

Research Site, Berlin

Research Site, Hong Kong

Research Site, Bangalore

Research Site, Pune

Research Site, New Delhi

Research Site, Ludhiana

Research Site, Vellore

Research Site, Florence

Research Site, Milan

Research Site, Vicenza

Research Site, Kashihara-shi

Research Site, Kawasaki-shi

Research Site, Kitakyushu-shi

Research Site, Nagoya

Research Site, Shinjuku-ku

Research Site, Suginami-ku

Research Site, Johannesburg Parktown

Research Site, Cape Town

Research Site, Barcelona

Research Site, Madrid

Research Site, Zurich

T2N 2T9

Research Site, Calgary

V6Z 1Y6

Research Site, Vancouver

RG24 9NA

Research Site, Basingstoke

CB2 2QQ

Research Site, Cambridge

G4 0SF

Research Site, Glasgow

E1 1BB

Research Site, London

NW3 2QG

Research Site, London

SE1 7EH

Research Site, London

Sponsors
All Listed Sponsors
collaborator

Swedish Orphan Biovitrum

INDUSTRY

lead

Bioverativ Therapeutics Inc.

INDUSTRY